The round was led by AZ-CICC Healthcare Investment Fund with participation from all existing investors and new investors including Korean Investment Partners, Delos Capital. Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets.

Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Their proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta Therapeutics' lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.